f Inmagene R&D Team expands with two new senior members joining the Company – Beranda Kaltim

Inmagene R&D Team expands with two new senior members joining the Company

SAN DIEGO and SHANGHAI and HANGZHOU, China, April 7, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") today announced that Dr. Anbo Xiang and Dr. Qian Xu joined the company. As CMO (China) and Senior VP, Operations, Dr. Xiang will be responsible for clinical development, operations, and regulatory affairs in China. As VP, Clinical Development, Dr. Xu will be responsible for clinical development and pharmacovigilance activities.

Dr. Xiang has nearly 30 years of experience in clinical research and development. Most recently, Dr. Xiang was CMO (non-oncology) at Qilu Pharmaceutical Group. Previously, Dr. Xiang was Senior Medical Director at Hengrui, and conducted pharmaceutical R&D at GSK Japan for 14 years. She led or made important contributions to the clinical development of multiple non-oncology products, including both small molecules and biologics. Dr. Xiang was a treating physician in China for 11 years and obtained her Medical Degree from School of Medicine, Sun Yat-sen University in China, and Ph.D. in Medical Sciences from Tsukuba University in Japan.

Dr. Xu has over 15 years of medical and clinical development experience in immunology-related therapeutic areas at large pharmaceutical companies, including Roche, Eli Lilly, Novartis and Hengrui. Most recently, as Senior Medical Director at Hengrui, Dr. Xu was responsible for the clinical development of innovative drugs in immunology-related therapeutic areas. Dr. Xu obtained her Medical Degree from Shanghai Jiao Tong University and Ph.D. from National University of Singapore, and she conducted post-doctoral research at University of California, Davis.

"Dr.'s Xiang and Xu are excellent additions to the Inmagene team. They have brought years of global clinical research and development experience, which will continue to enhance Inmagene's drug development capabilities," said Dr. Jonathan Wang, Inmagene's Chairman and CEO. "Inmagene, with approximately US$140 million financing to date, has been building a strong product pipeline. Their joining will enhance Inmagene's leadership position in innovative drug development in immunology-related therapeutic areas."

"It's a great pleasure to join Inmagene!" said Dr. Xiang. "My team and I will use world-class drug development knowledge and global market intelligence to guide cost-efficient innovation in China. We are conducting 'borderless innovation' to develop drugs for patients all over the world."

About Inmagene Biopharmaceuticals

Inmagene, with wholly owned subsidiaries in San Diego, Shanghai, and Hangzhou, is a leading biotech company focused on immunology-related therapeutic areas. Believing in "borderless innovation", the Inmagene team integrates the most efficient resources worldwide to develop drugs for worldwide patients. It also in-licenses products for the Asia markets and, together with its partners, carries out global development activities, including multi-regional clinical trials.

Inmagene is building a strong pipeline with over 10 drug candidates for immunological diseases. IMG-020, Inmagene's most advanced drug candidate, is in global clinical trials for multiple indications. The company has formed strategic partnerships with HUTCHMED (Nasdaq/AIM: HCM) and Affibody AB to develop and commercialize highly innovative drug candidates. In addition, Inmagene is developing 9 new molecules with global intellectual property rights from discovery stages.

from https://ift.tt/2Q03Pcb
Berikutnya Sebelumnya
Post Terkait :